关键词: 肝细胞癌, 索拉菲尼, 预后

Abstract: 【Abstract】〓Objective〓To investigate the usefulness of AFP response in sorafenib therapy patients with advanced hepatocellular carcinoma. Methods〓Forty-five patients who received sorafenib therapy with unresectable or metastatic HCC were included in this study from Aug 2008 to Aug 2012. Patients were set up into two groups according to the response of AFP. The relationship between different clinical variable factors and curative effects of sorafenib was analyzed by using Cox proportion hazard regression analysis and the side effects were also estimated. Results〓Of these cases, Fifteen patients in the AFP response group had tumor progression and 14 died, the disease control rate was 61.1%,while 21 patients in the AFP non-response group had tumor progression and 18 died,.the disease control rate was 51.8%. The median time to overall survival time was 13.5 months and 8 months(P<0.05) in AFP response group and AFP non-response group, respectively. Multivariate analysis showed that AFP response,cirrhosis,TNM stage and venous invasion were independent predictors of shorter overall survival time. Hand-foot syndrome, related gastrointestinal tract reaction and alopecia were the first three side effect events. Conclusion〓AFP response may be considered as an alternative marker for capture sorafenib activity in HCC. Cirrhosis, TNM stage and venous invasion maybe consider as another possible predict factor to sorafenib in advanced HCC patients.

Key words: Hepatocellular carcinoma, Sorafenib, Prognosis